m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03515)
Name
MMP-408
Synonyms
MMP-118; MMP-145; MMP-12 inhibitors (COPD); MMP-12 inhibitors (COPD), Pfizer; MMP-12 inhibitors (COPD), Wyeth
    Click to Show/Hide
Status
Investigative
TTD Drug ID
D00NPE
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Matrix metalloproteinase-12 (MMP-12)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for MMP-408. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MMP-408 through regulating the expression of Matrix metalloproteinase-12 (MMP-12). [1], [2]
References
Ref 1 The aberrant cross-talk of epithelium-macrophages via METTL3-regulated extracellular vesicle miR-93 in smoking-induced emphysema. Cell Biol Toxicol. 2022 Feb;38(1):167-183. doi: 10.1007/s10565-021-09585-1. Epub 2021 Mar 4.
Ref 2 Molecular determinants of a selective matrix metalloprotease-12 inhibitor: insights from crystallography and thermodynamic studies. J Med Chem. 2013 Feb 14;56(3):1149-59. doi: 10.1021/jm301574d. Epub 2013 Feb 5.